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Introduction
Secretoneurin (SN) represents a sensory, inflammatory
neuropeptide which was recently demonstrated to act as
an angiogenic and vasculogenic cytokine in vitro and in
vivo. The present study was conducted to test the hypoth-
esis that SN may be implicated in reparative angiogenesis.
Furthermore, we challenged the healing potential of SN
applied as a newly generated SN gene therapy vector in the
setting of limb ischemia.
Methods and results
We cloned the human SN coding sequence into the pAAV
plasmid containing a cytomegalovirus enhancer/pro-
moter sequence. To establish the bioactivity of the con-
structed SN plasmid (p-SN), we transfected p-SN into
COS cells and verified protein expression by SN-specific
RIA. Bioactivity of recombinant SN was shown by prolif-
erative and chemotactic activity on endothelial cells in
vitro. Unilateral limb ischemia was induced in C57/bl6
mice by femoral artery resection. By real time PCR, west-
ern blotting, SN-specific RIA and immunhistochemistry,
we documented that SN is up-regulated in ischemic mus-
cles. We tested whether SN gene therapy may exert cura-
tive effects in this ischemia model. Injection of the SN
plasmid into ischemic adductor muscles increased capil-
lary (670 vs. 350/mm2, n = 12, p = 0.02) and arteriole (16
vs. 8/mm2, n = 12, p = 0.04) density, reduced endothelial
cell apoptosis, and accelerated perfusion recovery as
shown by laser Doppler perfusion imaging (LDPI; ratio
ischemic/control leg after 28 days of ischemia: 1.1 vs. 0.7,
n = 12, p < 0.01) in comparison to p-GFP (green fluores-
cent protein)-treated mice. Furthermore, SN gene therapy
significantly reduced toe necrosis of ischemic limbs com-
pared to control animals (26% vs. 50%, n = 12, p < 0.05).
In bone marrow transplantation models, increased vascu-
larity of ischemic hind-limbs after SN gene therapy was
shown to be mediated, at least in part, by enhanced
recruitment of bone marrow-derived endothelial progen-
itor cells.
Conclusion
These results suggest that the novel angiogenic cytokine
secretoneurin is up-regulated by ischemia in skeletal mus-
cle cells. Furthermore, results from gene therapy in this
ischemia model suggest that secretoneurin represents a
promising new substance for therapeutic angiogenesis.
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